Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GUTS NASDAQ:IRIX NASDAQ:LUNG NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUTSFractyl Health$1.29+1.6%$1.12$0.83▼$3.48$63.87M2.277.36 million shs1.78 million shsIRIXIRIDEX$1.04-1.0%$1.21$0.78▼$1.95$17.67M0.5971,293 shs25,569 shsLUNGPulmonx$1.52-3.2%$1.66$1.47▼$9.37$63.97M0.42319,811 shs272,431 shsPSTVPlus Therapeutics$0.62+1.0%$0.56$0.16▼$2.31$60.96M0.8145.49 million shs4.90 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUTSFractyl Health+1.57%-3.73%+32.68%-27.93%-47.77%IRIXIRIDEX-0.95%0.00%-19.38%-17.46%-34.59%LUNGPulmonx-3.18%-3.80%-1.94%-51.75%-77.65%PSTVPlus Therapeutics+0.96%-11.17%+48.82%+66.89%-56.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUTSFractyl Health$1.29+1.6%$1.12$0.83▼$3.48$63.87M2.277.36 million shs1.78 million shsIRIXIRIDEX$1.04-1.0%$1.21$0.78▼$1.95$17.67M0.5971,293 shs25,569 shsLUNGPulmonx$1.52-3.2%$1.66$1.47▼$9.37$63.97M0.42319,811 shs272,431 shsPSTVPlus Therapeutics$0.62+1.0%$0.56$0.16▼$2.31$60.96M0.8145.49 million shs4.90 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUTSFractyl Health+1.57%-3.73%+32.68%-27.93%-47.77%IRIXIRIDEX-0.95%0.00%-19.38%-17.46%-34.59%LUNGPulmonx-3.18%-3.80%-1.94%-51.75%-77.65%PSTVPlus Therapeutics+0.96%-11.17%+48.82%+66.89%-56.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGUTSFractyl Health 2.60Moderate Buy$6.90434.88% UpsideIRIXIRIDEX 1.00SellN/AN/ALUNGPulmonx 2.40Hold$7.66404.23% UpsidePSTVPlus Therapeutics 3.00Buy$8.001,190.32% UpsideCurrent Analyst Ratings BreakdownLatest IRIX, GUTS, PSTV, and LUNG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025PSTVPlus TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025GUTSFractyl HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025IRIXIRIDEXWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LUNGPulmonxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PSTVPlus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/6/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.50 ➝ $21.009/27/2025GUTSFractyl HealthWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025IRIXIRIDEXWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LUNGPulmonxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PSTVPlus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/26/2025GUTSFractyl HealthHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGUTSFractyl Health$90K720.82N/AN/A$0.59 per share2.19IRIXIRIDEX$49.74M0.36N/AN/A$0.13 per share8.00LUNGPulmonx$83.79M0.74N/AN/A$2.17 per share0.70PSTVPlus Therapeutics$5.82M10.57N/AN/A($1.52) per share-0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGUTSFractyl Health-$68.69M-$2.06N/AN/AN/AN/A-584.35%-102.88%11/11/2025 (Estimated)IRIXIRIDEX-$8.91M-$0.33N/A∞N/A-10.95%-386.93%-17.42%11/11/2025 (Estimated)LUNGPulmonx-$56.39M-$1.43N/AN/AN/A-62.88%-69.76%-36.26%10/29/2025 (Estimated)PSTVPlus Therapeutics-$12.98M-$2.24N/AN/AN/A-357.85%N/A-117.72%11/13/2025 (Estimated)Latest IRIX, GUTS, PSTV, and LUNG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025PSTVPlus Therapeutics-$0.02N/AN/AN/A$1.50 millionN/A11/11/2025Q3 2025GUTSFractyl Health-$0.34N/AN/AN/AN/AN/A10/29/2025Q3 2025LUNGPulmonx-$0.40N/AN/AN/A$20.78 millionN/A8/14/2025Q2 2025PSTVPlus Therapeutics-$0.09-$0.01+$0.08-$0.01$1.08 million$1.39 million8/12/2025Q2 2025GUTSFractyl Health-$0.37-$0.53-$0.16-$0.57N/AN/A8/12/2025Q2 2025IRIXIRIDEX-$0.09-$0.06+$0.03-$0.06$13.10 million$13.57 million7/30/2025Q2 2025LUNGPulmonx-$0.40-$0.38+$0.02-$0.38$23.46 million$23.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGUTSFractyl HealthN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGUTSFractyl Health4.611.221.22IRIXIRIDEX62.291.961.34LUNGPulmonx0.545.354.63PSTVPlus TherapeuticsN/A1.261.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGUTSFractyl HealthN/AIRIXIRIDEX20.10%LUNGPulmonx91.04%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipGUTSFractyl Health26.10%IRIXIRIDEX7.40%LUNGPulmonx6.80%PSTVPlus Therapeutics0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGUTSFractyl Health10250.29 million37.16 millionN/AIRIXIRIDEX12016.99 million15.74 millionOptionableLUNGPulmonx25040.75 million37.98 millionOptionablePSTVPlus Therapeutics2099.26 million98.48 millionNot OptionableIRIX, GUTS, PSTV, and LUNG HeadlinesRecent News About These CompaniesPlus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest UpdateOctober 18 at 5:14 AM | marketbeat.comPlus Therapeutics (NASDAQ:PSTV) Upgraded by Zacks Research to "Strong-Buy" RatingOctober 15 at 7:37 AM | marketbeat.com5 Small Drug Stocks to Buy as the Industry Shows Some RecoveryOctober 14, 2025 | zacks.comAnalysts Set Plus Therapeutics, Inc. (NASDAQ:PSTV) Price Target at $8.00October 12, 2025 | americanbankingnews.comPlus Therapeutics' (PSTV) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 10, 2025 | marketbeat.comAscendiant Capital Markets Boosts Plus Therapeutics (NASDAQ:PSTV) Price Target to $21.00October 8, 2025 | americanbankingnews.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Rating of "Moderate Buy" from BrokeragesOctober 7, 2025 | marketbeat.comAscendiant Capital Maintains Plus Therapeutics (PSTV) Buy RecommendationOctober 6, 2025 | msn.comPlus Therapeutics (NASDAQ:PSTV) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst SaysOctober 6, 2025 | marketbeat.comPlus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United HealthcareSeptember 26, 2025 | insidermonkey.comD. Boral Capital Maintains Plus Therapeutics (PSTV) Buy RecommendationSeptember 25, 2025 | msn.comThese 3 Penny Stocks are Soaring Today: PLUS, EVAX, DVLTSeptember 25, 2025 | 247wallst.comPlus Therapeutics Pops on UNH PactSeptember 25, 2025 | baystreet.caPlus Therapeutics Shares Surge After UnitedHealthcare Coverage DealSeptember 25, 2025 | msn.comPlus Therapeutics stock soars after UnitedHealthcare agreementSeptember 25, 2025 | za.investing.comPlus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerSeptember 25, 2025 | globenewswire.comPlus on Upside on Cancer Institute PaymentSeptember 22, 2025 | baystreet.caPlus Therapeutics announces $1.9M advance payment from CPRITSeptember 22, 2025 | msn.comPlus Therapeutics receives $1.9M CPRIT payment for cancer programSeptember 22, 2025 | msn.comPlus Therapeutics, Inc. Secures $1.9 Million Payment from CPRIT as Part of $17.6 Million Grant for Leptomeningeal Cancer Treatment DevelopmentSeptember 22, 2025 | quiverquant.comQPlus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRITSeptember 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRIX, GUTS, PSTV, and LUNG Company DescriptionsFractyl Health NASDAQ:GUTS$1.29 +0.02 (+1.57%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.30 +0.01 (+1.16%) As of 10/17/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.IRIDEX NASDAQ:IRIX$1.04 -0.01 (-0.95%) Closing price 10/17/2025 03:50 PM EasternExtended Trading$1.06 +0.02 (+1.83%) As of 10/17/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Pulmonx NASDAQ:LUNG$1.52 -0.05 (-3.18%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.56 +0.04 (+2.63%) As of 10/17/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Plus Therapeutics NASDAQ:PSTV$0.62 +0.01 (+0.96%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.61 -0.01 (-1.94%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
